Pds Biotechnology (PDSB): Nant Capital, LLC disclosed a 19.9% stake in PDSB and may seek to influence the company 19.9%

19.9%

Stake

22.9M

Shares owned

Stake as of

Nov 9, 2026

Filed

Nov 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 12, 2026Company filing · Form 8-K · Agreement ended, Executive changeChanged a top executive or board member, and ended an important agreement (and 2 more items)“On September 12, 2026, pursuant to Section 5.14 of the previously disclosed Securities Purchase Agreement (the “ Purchase Agreement ”), dated September 7, 2026, by and among the Company and certain accredited investors (the Purchase Agreement was previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 8, 2026), the Board of Directors…”
2. Oct 18, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 18, 2026, each of Kamil Ali-Jackson, Esq., Stephen Glover, Gregory Freitag, J.D., CPA, and Otis Brawley, M.D. notified the Board of Directors (the “Board”) of PDS Biotechnology Corporation (the “Company”) of his or her resignation as a member of the Board, and of each committee of the Board on which he or she served, effective immediately.”

What came next

1. Nov 12, 20265% stakeNant Capital, LLC filed an activist stake (13D) of 19.9%
2. Nov 13, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Schedule 13D

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Pds Biotechnology

For Pds Biotechnology, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PDSB page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Pds Biotechnology

• SEC Form 4Mar 3, 2025
• SEC Form 4Mar 3, 2025

Everything OQRO holds on this company is on its PDSB page.